Overview Dividends

(PEN) Penumbra - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US70975L1070

Thrombectomy Devices, Access Catheters, Embolization Coils, Neurosurgical Tools

PEN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -36.21%
EPS Trend (3Y Correlation): 32.2%

PEN Revenue

Revenue Growth (3Y CAGR): 18.33%
Revenue Trend (3Y Correlation): 97.7%

Description: PEN Penumbra November 03, 2025

Penumbra, Inc. (NYSE:PEN) designs, develops, manufactures, and markets a broad portfolio of minimally invasive medical devices for peripheral and neurovascular applications. Its flagship offerings include the Indigo System for power aspiration thrombectomy, the Lightning Flash mechanical thrombectomy platform, and a suite of access catheters (Neuron, BENCHMARK, BMX, etc.) that support both arterial and venous interventions.

Beyond thrombectomy, Penumbra supplies neuro-embolization solutions such as the Coil 400 detachable coil and SMART COIL family, as well as peripheral embolization products like the Ruby Coil System and the POD occlusion device. The company also provides neurosurgical tools, notably the Artemis Neuro Evacuation Device for removing fluid and tissue from the ventricles and cerebrum. Sales are executed through a mix of direct field teams and regional distributors.

Key recent metrics: FY 2023 revenue reached approximately **$1.2 billion**, up ~15 % year-over-year, driven by strong adoption of the Indigo and Lightning platforms; operating margin expanded to **14 %**, reflecting higher mix of higher-margin neurovascular products; and the balance sheet holds **~$800 million** in cash and short-term investments, providing runway for R&D and potential acquisitions.

Sector drivers that underpin Penumbra’s growth outlook include an aging U.S. population, rising incidence of acute ischemic stroke and peripheral artery disease, and favorable reimbursement trends for endovascular therapies. Competitive pressure from larger players (e.g., Medtronic, Stryker) is mitigated by Penumbra’s focus on specialty aspiration technologies and a pipeline of next-generation catheters slated for FDA clearance in 2025.

For a deeper quantitative dive into PEN’s valuation metrics and scenario analysis, the ValueRay platform offers a free, data-driven dashboard worth checking out.

PEN Stock Overview

Market Cap in USD	9,168m
Sub-Industry	Health Care Equipment
IPO / Inception	2015-09-18

PEN Stock Ratings

Growth Rating	25.0%
Fundamental	78.9%
Dividend Rating	-
Return 12m vs S&P 500	-1.36%
Analyst Rating	4.44 of 5

PEN Dividends

Currently no dividends paid

PEN Growth Ratios

Growth Correlation 3m	-51.1%
Growth Correlation 12m	-3.3%
Growth Correlation 5y	-1.3%
CAGR 5y	14.71%
CAGR/Max DD 3y (Calmar Ratio)	0.28
CAGR/Mean DD 3y (Pain Ratio)	0.61
Sharpe Ratio 12m	-0.77
Alpha	0.86
Beta	0.688
Volatility	44.36%
Current Volume	1111.2k
Average Volume 20d	355k
Stop Loss	255.5 (-3.4%)
Signal	0.75

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (147.7m TTM) > 0 and > 6% of Revenue (6% = 76.8m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 2.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 70.91% (prev 69.93%; Δ 0.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 201.5m > Net Income 147.7m (YES >=105%, WARN >=100%)

Net Debt (-201.2m) to EBITDA (193.7m) ratio: -1.04 <= 3.0 (WARN <= 3.5)

Current Ratio 6.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (39.2m) change vs 12m ago 1.17% (target <= -2.0% for YES)

Gross Margin 66.47% (prev 62.51%; Δ 3.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 79.78% (prev 73.88%; Δ 5.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 132.9 (EBITDA TTM 193.7m / Interest Expense TTM 1.31m) >= 6 (WARN >= 3)

Altman Z'' 4.98

(A) 0.54 = (Total Current Assets 1.07b - Total Current Liabilities 157.8m) / Total Assets 1.67b

(B) 0.09 = Retained Earnings (Balance) 144.5m / Total Assets 1.67b

(D) 0.39 = Book Value of Equity 147.7m / Total Liabilities 380.9m

Total Rating: 4.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 78.89

1. Piotroski 7.0pt = 2.0

2. FCF Yield 1.80% = 0.90

3. FCF Margin 12.63% = 3.16

4. Debt/Equity 0.17 = 2.49

5. Debt/Ebitda -1.04 = 2.50

6. ROIC - WACC (= 6.30)% = 7.88

7. RoE 12.41% = 1.03

8. Rev. Trend 97.72% = 7.33

9. EPS Trend 32.16% = 1.61

What is the price of PEN shares?

As of November 07, 2025, the stock is trading at USD 264.61 with a total of 1,111,215 shares traded.
Over the past week, the price has changed by +14.28%, over one month by +3.52%, over three months by +10.26% and over the past year by +13.23%.

Is Penumbra a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Penumbra (NYSE:PEN) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 78.89 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PEN is around 237.07 USD . This means that PEN is currently overvalued and has a potential downside of -10.41%.

Is PEN a buy, sell or hold?

Penumbra has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy PEN.

Strong Buy: 12
Buy: 2
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PEN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	304.5	15.1%
Analysts Target Price	304.5	15.1%
ValueRay Target Price	264	-0.2%

PEN Fundamental Data Overview November 06, 2025

Market Cap USD = 9.17b (9.17b USD * 1.0 USD.USD)
P/E Trailing = 62.1905
P/E Forward = 50.7614
P/S = 7.1616
P/B = 7.6401
P/EG = 0.5997
Beta = 0.688
Revenue TTM = 1.28b USD
EBIT TTM = 174.6m USD
EBITDA TTM = 193.7m USD
Long Term Debt = 21.8m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 15.3m USD (from shortTermDebt, last quarter)
Debt = 220.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -201.2m USD (from netDebt column, last quarter)
Enterprise Value = 8.97b USD (9.17b + Debt 220.5m - CCE 421.8m)
Interest Coverage Ratio = 132.9 (Ebit TTM 174.6m / Interest Expense TTM 1.31m)
FCF Yield = 1.80% (FCF TTM 161.6m / Enterprise Value 8.97b)
FCF Margin = 12.63% (FCF TTM 161.6m / Revenue TTM 1.28b)
Net Margin = 11.54% (Net Income TTM 147.7m / Revenue TTM 1.28b)
Gross Margin = 66.47% ((Revenue TTM 1.28b - Cost of Revenue TTM 429.2m) / Revenue TTM)
Gross Margin QoQ = 65.99% (prev 66.60%)
Tobins Q-Ratio = 5.35 (Enterprise Value 8.97b / Total Assets 1.67b)
Interest Expense / Debt = 0.14% (Interest Expense 319.0k / Debt 220.5m)
Taxrate = 0.09% (40.0k / 45.3m)
NOPAT = 174.4m (EBIT 174.6m * (1 - 0.09%))
Current Ratio = 6.75 (Total Current Assets 1.07b / Total Current Liabilities 157.8m)
Debt / Equity = 0.17 (Debt 220.5m / totalStockholderEquity, last quarter 1.29b)
Debt / EBITDA = -1.04 (Net Debt -201.2m / EBITDA 193.7m)
Debt / FCF = -1.25 (Net Debt -201.2m / FCF TTM 161.6m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.82% (Net Income 147.7m / Total Assets 1.67b)
RoE = 12.41% (Net Income TTM 147.7m / Total Stockholder Equity 1.19b)
RoCE = 14.40% (EBIT 174.6m / Capital Employed (Equity 1.19b + L.T.Debt 21.8m))
RoIC = 14.65% (NOPAT 174.4m / Invested Capital 1.19b)
WACC = 8.35% (E(9.17b)/V(9.39b) * Re(8.55%) + D(220.5m)/V(9.39b) * Rd(0.14%) * (1-Tc(0.00)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.06%
[DCF Debug] Terminal Value 79.81% ; FCFE base≈141.2m ; Y1≈174.2m ; Y5≈297.3m
Fair Price DCF = 117.6 (DCF Value 4.59b / Shares Outstanding 39.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 32.16 | EPS CAGR: -36.21% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.72 | Revenue CAGR: 18.33% | SUE: 3.13 | # QB: 3

Additional Sources for PEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle